P. Meyers, R. Gorlick, and . Osteosarcoma, Pediatric Clinics of, North America, vol.44, pp.973-989, 1997.

C. Stiller, S. Bielack, G. Jundt, and E. Steliarova-foucher, Bone tumours in European children and adolescents, 1978???1997. Report from the Automated Childhood Cancer Information System project, European Journal of Cancer, vol.42, issue.13, pp.2124-2135, 2006.
DOI : 10.1016/j.ejca.2006.05.015

M. Link, A. Goorin, A. Miser, A. Green, C. Pratt et al., The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity, New England Journal of Medicine, vol.314, issue.25, pp.1600-1606, 1986.
DOI : 10.1056/NEJM198606193142502

P. Meyers, G. Heller, J. Healey, A. Huvos, J. Lane et al., Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience., Journal of Clinical Oncology, vol.10, issue.1, pp.5-15, 1992.
DOI : 10.1200/JCO.1992.10.1.5

S. Bielack, B. Kempf-bielack, G. Delling, G. Exner, S. Flege et al., Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols, Journal of Clinical Oncology, vol.20, issue.3, pp.776-90, 2002.
DOI : 10.1200/JCO.2002.20.3.776

D. Hawkins and C. Arndt, Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy, Cancer, vol.5, issue.11, pp.2447-2456, 2003.
DOI : 10.1002/cncr.11799

A. Nardin, M. Lefebvre, K. Labroquère, O. Faure, and J. Abastado, Liposomal Muramyl Tripeptide Phosphatidylethanolamine: Targeting and Activating Macrophages for Adjuvant Treatment of Osteosarcoma, Current Cancer Drug Targets, vol.6, issue.2, pp.123-156, 2006.
DOI : 10.2174/156800906776056473

E. Kleinerman, K. Erickson, A. Schroit, W. Fogler, and I. Fidler, Activation of Tumoricidal Properties in Human Blood Monocytes by Liposomes Containing Lipophilic Muramyl Tripeptide, Cancer Res, vol.43, pp.2010-2014, 1983.

W. Fogler and I. Fidler, Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages, Cancer Res, vol.45, pp.14-18, 1985.

T. Asano, A. Mcwatters, T. An, K. Matsushima, and E. Kleinerman, Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleu- kin-6 and interleukin-8 gene expression in human monocytes, J Pharmacol Exp Ther, vol.268, pp.1032-1041, 1994.

P. Anderson, Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma, Future Oncology, vol.3, issue.3, pp.333-343, 2006.
DOI : 10.1054/bjoc.1999.0917

P. Meyers, Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma, Expert Review of Anticancer Therapy, vol.50, issue.8, pp.1035-1084, 2009.
DOI : 10.1002/pbc.21296

S. Cryan, Carrier-based strategies for targeting protein and peptide drugs to the lungs, The AAPS Journal, vol.7, issue.1, pp.20-41, 2005.
DOI : 10.1208/aapsj070104

W. Zamboni, Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents, Clinical Cancer Research, vol.11, issue.23, pp.8230-8234, 2005.
DOI : 10.1158/1078-0432.CCR-05-1895

E. Buddingh, M. Kuijjer, R. Duim, H. Bürger, K. Agelopoulos et al., Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents, Clinical Cancer Research, vol.17, issue.8, pp.2110-2119, 2011.
DOI : 10.1158/1078-0432.CCR-10-2047

P. Meyers, C. Schwartz, M. Krailo, E. Kleinerman, D. Betcher et al., Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate, Journal of Clinical Oncology, vol.23, issue.9, pp.2004-2015, 2005.
DOI : 10.1200/JCO.2005.06.031

A. Provisor, L. Ettinger, J. Nachman, M. Krailo, J. Makley et al., Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group., Journal of Clinical Oncology, vol.15, issue.1, pp.76-84, 1997.
DOI : 10.1200/JCO.1997.15.1.76

P. Meyers, C. Schwartz, M. Krailo, J. Healey, M. Bernstein et al., Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival???A Report From the Children's Oncology Group, Journal of Clinical Oncology, vol.26, issue.4, pp.633-641, 2008.
DOI : 10.1200/JCO.2008.14.0095

D. Heymann, B. Ory, F. Blanchard, M. Heymann, P. Coipeau et al., Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005.
DOI : 10.1016/j.bone.2005.02.020

B. Ory, M. Heymann, A. Kamijo, F. Gouin, D. Heymann et al., Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice, Cancer, vol.91, issue.11, pp.2522-2529, 2005.
DOI : 10.1007/978-1-4419-9129-4_10

D. Ribatti, G. Mangialardi, and A. Vacca, Stephen Paget and the ???seed and soil??? theory of metastatic dissemination, Clinical and Experimental Medicine, vol.6, issue.4, pp.145-154, 2006.
DOI : 10.1007/s10238-006-0117-4

J. Chirgwin and T. Guise, Molecular Mechanisms of Tumor-Bone Interactions in Osteolytic Metastases, Critical Reviews?? in Eukaryotic Gene Expression, vol.10, issue.2, pp.159-78, 2000.
DOI : 10.1615/CritRevEukarGeneExpr.v10.i2.50

D. Heymann, B. Ory, F. Gouin, J. Green, and F. Rédini, Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-380, 2004.
DOI : 10.1016/j.molmed.2004.05.007

A. Lipton and J. Seaman, Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases, Cancer, vol.91, pp.1191-1200, 2001.

S. Boissier, M. Ferreras, O. Peyruchaud, S. Magnetto, F. Ebetino et al., Bisphosphonates inhibit breast and prostate carcinoma cell invasion , an early event in the formation of bone metastases, Cancer Res, vol.60, pp.2949-2954, 2000.

H. Gober, M. Kistowska, L. Angman, P. Jenö, L. Mori et al., Human T Cell Receptor ???? Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells, The Journal of Experimental Medicine, vol.263, issue.2, pp.163-171, 2003.
DOI : 10.1038/sj.onc.1203002

F. Saad, D. Gleason, R. Murray, S. Tchekmedyian, P. Venner et al., A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma, JNCI Journal of the National Cancer Institute, vol.14, issue.3, pp.1458-68, 2002.
DOI : 10.2165/00002018-199614030-00003

L. Rosen, D. Gordon, S. Tchekmedyian, R. Yanagihara, V. Hirsh et al., Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial???The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group, Journal of Clinical Oncology, vol.21, issue.16, pp.3150-3157, 2003.
DOI : 10.1200/JCO.2003.04.105

S. Leung, J. Jackson, H. Miyake, H. Burt, and M. Gleave, Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors, The Prostate, vol.57, issue.2, pp.156-163, 2000.
DOI : 10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G

R. Chapurlat, M. Laroche, T. Thomas, S. Rouanet, P. Delmas et al., Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia???a randomized placebo-controlled trial, Osteoporosis International, vol.81, issue.2, pp.311-331, 2013.
DOI : 10.1007/s00223-007-9076-3

G. Rosen, R. Marcove, B. Caparros, A. Nirenberg, C. Kosloff et al., Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery, Cancer, vol.36, issue.6, pp.2163-2177, 1979.
DOI : 10.1007/978-3-642-95227-2_24

A. Chou, E. Kleinerman, M. Krailo, Z. Chen, D. Betcher et al., Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma, Cancer, vol.39, issue.22, pp.5339-5348, 2009.
DOI : 10.1016/S0959-8049(02)00747-5

G. Moriceau, B. Ory, B. Gobin, F. Verrecchia, F. Gouin et al., Therapeutic Approach of Primary Bone Tumours by Bisphosphonates, Current Pharmaceutical Design, vol.16, issue.27, pp.2981-2987, 2010.
DOI : 10.2174/138161210793563554
URL : https://hal.archives-ouvertes.fr/inserm-00511241

C. Khanna, T. Fan, R. Gorlick, L. Helman, E. Kleinerman et al., Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma, Clinical Cancer Research, vol.20, issue.16, pp.4200-4209, 2014.
DOI : 10.1158/1078-0432.CCR-13-2574

E. Macewen, I. Kurzman, R. Rosenthal, B. Smith, P. Manley et al., Therapy for Osteosarcoma in Dogs With Intravenous Injection of Liposome-Encapsulated Muramyl Tripeptide, JNCI Journal of the National Cancer Institute, vol.81, issue.12, pp.935-943, 1989.
DOI : 10.1093/jnci/81.12.935

S. Botter, D. Neri, and B. Fuchs, Recent advances in osteosarcoma, Current Opinion in Pharmacology, vol.16, pp.15-23, 2014.
DOI : 10.1016/j.coph.2014.02.002

S. Sone, T. Utsugi, P. Tandon, and M. Ogawara, A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state, Cancer Immunology Immunotherapy, vol.22, issue.3, pp.191-197, 1986.
DOI : 10.1007/BF00200032

J. Pahl, K. Kwappenberg, E. Varypataki, S. Santos, M. Kuijjer et al., Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-??, Journal of Experimental & Clinical Cancer Research, vol.33, issue.1, p.27, 2014.
DOI : 10.1126/science.1198443

I. Saiki, S. Sone, W. Fogler, E. Kleinerman, G. Lopez-berestein et al., Synergism between Human Recombinant ?-Interferon and Muramyl Dipeptide Encapsulated in Liposomes for Activation of Antitumor Properties in Human Blood Monocytes, Cancer Res, vol.45, pp.6188-6193, 1985.

G. Dicuonzo, B. Vincenzi, D. Santini, G. Avvisati, L. Rocci et al., and IL-6, Journal of Interferon & Cytokine Research, vol.23, issue.11, pp.649-54, 2003.
DOI : 10.1089/107999003322558782

L. Kager, U. Pötschger, and S. Bielack, Review of mifamurtide in the treatment of patients with osteosarcoma, Therapeutics and Clinical Risk Management, vol.6, pp.279-86, 2010.
DOI : 10.2147/TCRM.S5688

L. Endo-munoz, A. Evdokiou, and N. Saunders, The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1826, issue.2
DOI : 10.1016/j.bbcan.2012.07.003

E. Rietkötter, K. Menck, A. Bleckmann, K. Farhat, M. Schaffrinski et al., Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion, Oncotarget, vol.4, issue.9, pp.1449-1460, 2013.
DOI : 10.18632/oncotarget.1201

W. Strober, P. Murray, A. Kitani, and T. Watanabe, Signalling pathways and molecular interactions of NOD1 and NOD2, Nature Reviews Immunology, vol.1029, issue.1, pp.9-20, 2006.
DOI : 10.1196/annals.1309.029